Dr. Wysota's research aims to identify novel therapeutic targets in acute myeloid leukemia (AML) and to understand the role of inflammation in clonal hematopoiesis, particularly in TET2-mutated cases. He has co-authored studies on RNA shielding of p65 to potentiate oncogenic inflammation in TET2-mutated clonal hematopoiesis and on novel therapeutic targets in AML. Additionally, he has contributed to research on the regulation of IL-17F-producing Th17 cells in CLL and the management of borderline-resectable pancreatic ductal adenocarcinoma. His clinical interest's involves the diagnosis and treatment of various hematologic malignancies, with a focus on B-cell lymphomas.
Michael Wysota, MD
Assistant Professor
Contact Information
834 Chestnut Street
Suite 300
Philadelphia, PA 19107
215-955-8874
215-955-9641 fax
Assistant Professor
RESEARCH & CLINICAL INTEREST
Education
Medical School
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY - 2018
Residency
Internal Medicine, Montefiore Medical Center, Bronx, NY - 2021
Fellowship
Hematology/Oncology, Montefiore Medical Center, Bronx, NY - 2024
Publications
- Fine particulate matter exposure is linked to worse myeloma outcomes in a diverse urban cohort
- Environmental Pollution Triggers Inflammation In Vivo and is Associated With Higher Risk MDS in an Urban Cohort
- Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
- RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis
- Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
Certifications
- Board Certified Internal Medicine, 2021
- Board Certified Hematology, 2023
Research & Clinical Interest
My current research focus is on lymphoid malignancies particularly B cell lymphomas including Diffuse Large B Cell Lymphoma, CLL, Follicular lymphoma, Mantle Cell Lymphoma, etc.